Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities

Monica Margoni; Francesca Rinaldi; Paola Perini; Paolo Gallo

doi:10.3389/fneur.2021.676095

Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities

Front Neurol. 2021 May 17:12:676095. doi: 10.3389/fneur.2021.676095. eCollection 2021.

Authors

Monica Margoni^{1

2}, Francesca Rinaldi¹, Paola Perini¹, Paolo Gallo^{1

3}

Affiliations

¹ Multiple Sclerosis Centre of the Veneto Region (CeSMuV), University Hospital of Padua, Padua, Italy.
² Padova Neuroscience Centre, University of Padua, Padua, Italy.
³ Department of Neurosciences, Medical School, University of Padua, Padua, Italy.

Abstract

Treatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) patients. There are an increasing number of new therapeutic agents for AOMS, and many will be formally studied for use also in POMS. However, there are important efficacy and safety concerns regarding the use of these therapies in children and young adults. This review will discuss the current state of the art of POMS therapy and will focus on the newer therapies (oral and infusion disease-modifying drugs) and on those still currently under investigation.

Keywords: efficacy; first-line therapies; pediatric onset multiple sclerosis; safety; second-line therapies.

Publication types

Review